P. Tamarozzi

Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors

Background Immune-related adverse events (irAEs) represent a challenge in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (IO). Baseline circulating immunophenotype may identify patients at increased irAEs risk.Methods This observational study i...